Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Hypermethylation of the ribosomal DNA coding sequence and disordered transcription factor binding as hallmarks of acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYun Huang

Discussion

Loading...

Member takes

Overview

Analysis reveals hypermethylation in ribosomal DNA as a biomarker in acute myeloid leukemia, suggesting implications for treatment strategies using hypomethylating agents.

Key Points

  • Higher DNA methylation levels in ribosomal DNA were noted in patients with acute myeloid leukemia, indicating a potential prognostic marker.
  • Data from 484 AML samples were analyzed to confirm distinct hypermethylation signatures significant in disease progression.
  • Epigenome editing techniques were proposed to understand the relationship between DNA methylation and transcription factor binding in ribosomal DNA.
  • The study highlights unique DNA methylation changes in hematological malignancies that may influence ribosomal biogenesis and therapeutic responses.

Cite This Study

Yun Huang (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d78ehttps://doi.org/10.1182/blood-2025-1451
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epigenetic markers expand genetic risk estimation in acute myeloid leukemia2026
  2. 2Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML2025
  3. 3DNA methylation markers assessed at birth are associated with future development of pediatric acute lymphoblastic leukemia2025
  4. 4Regulation of ribosomal RNA synthesis in Acute Myeloid Leukemia2025
  5. 5Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood2025